RGS 0.00% 12.0¢ regeneus ltd

Yes, patent infringement control is an issue in China and other...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 76 Posts.
    lightbulb Created with Sketch. 5
    Yes, patent infringement control is an issue in China and other places too. Yes, they can copy products, mainly in manufacturing though.
    But in RGS' case, this would require creating an entire line of MSCs, extract secretions (which is NOT the patent in question here), and use secretions within a cream (The patent is the use of MSC secretions for skin conditions, not how to develop a MSC line and extract secretions).
    So, in this case, I think RGS is fine: their cream using MSC secretions is well protected and the technology not easy to copy.
 
watchlist Created with Sketch. Add RGS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.